ORIGINAL RESEARCH article

Front. Public Health

Sec. Infectious Diseases: Epidemiology and Prevention

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1484866

This article is part of the Research TopicNovel Interventions for the Prevention and Control of Communicable DiseaseView all 20 articles

Prevalence of virological failure and associated factors among adult individuals on HAART on highly active anti retro viral treatment in public health facilities at Tulu Bolo Town Southwest Shoa, Ethiopia, 2024

Provisionally accepted
  • 1Department of Public Health, Tulu Bolo General Hospital, Southwest Shoa, Tulu Bolo, Ethiopia, Woliso, Ethiopia
  • 2College of Medicine and Health Sciences, Ambo University, Ambo, Oromia Region, Ethiopia
  • 3Independent researcher, Department of Public Health, Dawo District Health office, Southwest Shoa, Oromia, Ethiopia

The final, formatted version of the article will be published soon.

The goal of antiretroviral therapy for HIV infection is to achieve and maintain virologic suppression. Review of charts of adult HIV-positive patients at public health facilities in Tulu Bolo Town reveals that approximately 6.07% of patients did not respond to first-line antiretroviral medication. The identified gap indicates that the study area's virologic failure prevalence and contributing factors are not well-documented. Thus, this study's objectives are to evaluate prevalence and close a knowledge gap about factors associated with virological failure. Objective: To assess the prevalence of virological failure and associated factors among patients taking highly active anti-Retroviral therapy in Tulu Bolo Town Health facilities, Oromia, Ethiopia, 2024. Methods: Health facility based cross sectional study was conducted at Tulu Bolo town in public health facilities from September 30, 2024 to October 30, 2024. Total sample sizes of 274 records of clients were selected using simple random sampling technique. Data was cleaned and entered in to EPI info version 7.2.0.1 and exported to SPSS version 20.0 for further analysis. The association was identified using binary logistic regression model. An adjusted odds ratio with 95% confidence intervals (CI) was computed to identify the presence and strength of association.Finally, statistically significant variables were declared at p-value < 0.05 along with 95% CI.Results: A total of 274 charts of HIV positive clients were included in the study. The magnitude of virologic failure was 12.8% (95%CI 9%, 17%). Baseline CD4 count < 200 (AOR 6.1, 95%CI 2.06, 18.43), Clients infected with TB (AOR 4.8 95%CI (1.78, 12.96), treatment interruption (AOR 3.05, 95% CI 1.06, 8.77) and adherence (AOR 3.67, 95%CI 1.39, 9.66) were statistically significant association.The overall prevalence of virologic failure of this study was high as compared to standard. Baseline CD4 Count, TB infection, treatment interruption and Adherence were significant factors. Health facility ART provider and HIV/AIDS program manager should give special attention for Clients with history of TB co infection and CD4 count < 200 needs care and support and providing TB preventive therapy.

Keywords: First line Anti-retro viral therapy, virological failure, Tulu Bolo, Virologic suppression, HIV positive

Received: 22 Aug 2024; Accepted: 28 May 2025.

Copyright: © 2025 Lamesa, Teshoma, Oljira Desta, Regassa and Waqkene. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ashenafi Lamesa, Department of Public Health, Tulu Bolo General Hospital, Southwest Shoa, Tulu Bolo, Ethiopia, Woliso, Ethiopia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.